0.00Open0.05Pre Close0 Volume17 Open Interest7.50Strike Price0.00Turnover526.68%IV539.83%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1186Delta0.1565Gamma23.60Leverage Ratio-0.0081Theta0.0000Rho2.80Eff Leverage0.0005Vega
Vor Biopharma Stock Discussion
Was watching this Friday painting a beautiful chart not sure why I didn't enter but I will likely enter Monday.
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
• Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant
• Trem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic window
...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
No comment yet